CEBPA and acute myeloid leukemia: Due to high chemotherapy responsiveness, familial CEBPA-mutated AML generally portends a favorable prognosis in comparison to cases with sporadic mutations, with 10-year survival rates of 67%, superior to spontaneous bi-allelic (54%) and single CEBPA mutations (29%) (15).